The story of the erectile dysfunction drug presents a complex picture for investors. While the initial release generated substantial profits, the expiration of its intellectual property protection opened the floodgates https://getsocialnetwork.com/story7223775/the-copyright-and-the-pharmaceutical-industry-a-precarious-opportunity